[go: up one dir, main page]

NI201000168A - Aminas de tiazolopiridina-2-iloxi-fenil y tiazolopirazina-2-iloxi-fenil como moduladores del leucotrieno a4 hidrolasa. - Google Patents

Aminas de tiazolopiridina-2-iloxi-fenil y tiazolopirazina-2-iloxi-fenil como moduladores del leucotrieno a4 hidrolasa.

Info

Publication number
NI201000168A
NI201000168A NI201000168A NI201000168A NI201000168A NI 201000168 A NI201000168 A NI 201000168A NI 201000168 A NI201000168 A NI 201000168A NI 201000168 A NI201000168 A NI 201000168A NI 201000168 A NI201000168 A NI 201000168A
Authority
NI
Nicaragua
Prior art keywords
phenyl
iloxi
thiazolopyrazine
thiazolopyridine
modulators
Prior art date
Application number
NI201000168A
Other languages
English (en)
Inventor
M Bacani Genesis
Broggini Diego
Y Cheung Eugene
C Chrovian Christa
Deng Xiaohu
M Fourie Anne
Gomez Laurent
A Grice Cheryl
M Kearney Aaron
M Landry-Bayle Adrienne
Lee-Dutra Alice
T Liang Jimmy
Lochner Susanne
S Mani Neelakandha
Santillán Alejandro Jr
C Sappey Kathleen
Sepassi Kia
M Tanis Virginia
T Wickboldt Alvah
J M Wiener John
Zinser Hartmut
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NI201000168A publication Critical patent/NI201000168A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Se describen compuestos de aminas de tiazolopiridina-2-iloxi-fenil y tiazolopirazina-2-iloxi-fenil los cuales son útiles como moduladores (LTA4H) del LTA4 hidrolasa. Estos compuestos se pueden utilizar en composiciones farmacéuticas y métodos para la modulación del LTA4H y para el tratamiento de estados de enfermedad, trastornos y condiciones mediados por la actividad del LTA4 hidrolasa.
NI201000168A 2008-04-11 2010-10-11 Aminas de tiazolopiridina-2-iloxi-fenil y tiazolopirazina-2-iloxi-fenil como moduladores del leucotrieno a4 hidrolasa. NI201000168A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4434908P 2008-04-11 2008-04-11
US14912909P 2009-02-02 2009-02-02

Publications (1)

Publication Number Publication Date
NI201000168A true NI201000168A (es) 2015-05-27

Family

ID=41130551

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201000168A NI201000168A (es) 2008-04-11 2010-10-11 Aminas de tiazolopiridina-2-iloxi-fenil y tiazolopirazina-2-iloxi-fenil como moduladores del leucotrieno a4 hidrolasa.

Country Status (36)

Country Link
US (3) US7939527B2 (es)
EP (2) EP2336125B1 (es)
JP (2) JP5530423B2 (es)
KR (1) KR101228378B1 (es)
CN (1) CN102056933B (es)
AR (1) AR072353A1 (es)
AU (1) AU2009234140B2 (es)
BR (1) BRPI0911336A2 (es)
CA (1) CA2721099C (es)
CL (1) CL2009000877A1 (es)
CO (1) CO6260069A2 (es)
CY (1) CY1114628T1 (es)
DK (2) DK2336125T3 (es)
EA (1) EA018802B1 (es)
EC (1) ECSP10010558A (es)
ES (2) ES2440746T3 (es)
HK (2) HK1152041A1 (es)
HN (1) HN2010002074A (es)
HR (2) HRP20130278T1 (es)
IL (2) IL208480A (es)
JO (1) JO2911B1 (es)
MX (1) MX2010011154A (es)
MY (1) MY157597A (es)
NI (1) NI201000168A (es)
NZ (2) NZ588341A (es)
PE (1) PE20091779A1 (es)
PH (1) PH12013500094B1 (es)
PL (2) PL2268646T3 (es)
PT (2) PT2268646E (es)
RS (2) RS53081B (es)
SI (2) SI2268646T1 (es)
SV (1) SV2010003694A (es)
TW (2) TW201420100A (es)
UY (1) UY31760A (es)
WO (1) WO2009126806A2 (es)
ZA (1) ZA201008054B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1976828T (pt) 2005-12-29 2017-03-10 Celtaxsys Inc Derivados de diamina como inibidores de leucotrieno a4 hidrolase
AU2009234140B2 (en) * 2008-04-11 2013-04-11 Janssen Pharmaceutica Nv Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase
CN104487435A (zh) 2012-03-06 2015-04-01 勃林格殷格翰国际有限公司 用于抑制白三烯生成的苯并二氧杂环己烷与其他活性剂的组合
EP2822942B1 (en) * 2012-03-06 2017-05-10 Boehringer Ingelheim International GmbH Benzodioxanes for inhibiting leukotriene production
WO2014014874A1 (en) 2012-07-17 2014-01-23 Boehringer Ingelheim International Gmbh Pyrazole derivatives which inhibit leukotriene production
EP2746259A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
EP2746260A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
RU2686101C2 (ru) 2013-03-12 2019-04-24 Селтакссис, Инк. Способы ингибирования лейкотриен- а4-гидролазы
CA2906035A1 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
JP6562898B2 (ja) * 2013-03-14 2019-08-21 セルタクシス，インコーポレイテッド ロイコトリエンａ４加水分解酵素の阻害剤
JP7386815B2 (ja) 2018-05-31 2023-11-27 セルタクシー、エルエルシー 呼吸器疾患患者の肺増悪を軽減する方法
EP3908278A4 (en) * 2019-01-11 2022-09-28 Naegis Pharmaceuticals Inc. LEUCOTRIENE SYNTHESIS INHIBITORS

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008A (en) * 1847-03-13 Machinery for cleaning
IL59004A0 (en) 1978-12-30 1980-03-31 Beecham Group Ltd Substituted benzamides their preparation and pharmaceutical compositions containing them
US4424358A (en) 1979-01-16 1984-01-03 Delalande S.A. β-3-Amino nor-tropane compounds
US4329466A (en) 1979-01-16 1982-05-11 Delalande S.A. Certain nor-tropan-8-amine-3-aryl or heteroaryl derivatives
FR2476088A2 (fr) 1979-01-16 1981-08-21 Delalande Sa Nouveaux derives du nor-tropane, leur procede de preparation et leur application en therapeutique
US4321378A (en) 1979-01-16 1982-03-23 Delalande S.A. 8-(5-Pyrimidinecarboxamide)nor-tropane derivatives
FR2446823A1 (fr) 1979-01-16 1980-08-14 Delalande Sa Nouveaux derives du nor-tropane, leur procede de preparation et leur application en therapeutique
US4352802A (en) 1980-06-10 1982-10-05 Beecham Group Limited Bicyclo[3.3.1]nonyl-benzamide
NZ199080A (en) 1980-12-12 1984-07-31 Beecham Group Ltd 2-alkoxy-4-amino-5-alkylsulphonyl-n-(3beta-(8-hydrocarbyl-8-azabicyclo (3,2,1)octyl))benzamides
US4432983A (en) 1981-04-30 1984-02-21 Research Corporation Conformationally restricted histamine H2 -receptor antagonists containing a tropane ring
DE3137996A1 (de) * 1981-09-24 1983-04-28 Hoechst Ag, 6230 Frankfurt Heterocyclische phenylaether, verfahren zu deren herstellung und diese enthaltende herbizide mittel
US4571396A (en) * 1984-04-16 1986-02-18 Warner-Lambert Company Antibacterial agents
US4873346A (en) * 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
NZ222047A (en) 1986-10-08 1991-01-29 Bristol Myers Co Quinoline - or naphthyridine - carboxylic acid anti-bacterial agents
DK171349B1 (da) * 1986-11-14 1996-09-16 Hoffmann La Roche Tetrahydronaphthalenderivater, fremgangsmåde til fremstilling deraf, lægemidler indeholdende forbindelserne samt anvendelse af forbindelserne til fremstilling af lægemidler
JPS63170356A (ja) 1986-12-30 1988-07-14 Yamanouchi Pharmaceut Co Ltd アニリン誘導体及びその製造法
FI91859C (fi) * 1987-06-17 1994-08-25 Eisai Co Ltd Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
US5070094A (en) 1989-09-05 1991-12-03 G. D. Searle & Co. N-benzyltropaneamides
US5220063A (en) * 1991-05-10 1993-06-15 Hoechst Celanese Corporation Method for the preparation of arylalkanolacylamides
US5296486A (en) * 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
US5472964A (en) * 1992-12-22 1995-12-05 Merck Frosst Canada, Inc. Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
TW251287B (es) 1993-04-30 1995-07-11 Nissei Co Ltd
US5585492A (en) 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
US6506876B1 (en) 1994-10-11 2003-01-14 G.D. Searle & Co. LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
US5700816A (en) 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US6632976B1 (en) * 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
DK0880363T3 (da) 1996-02-13 2003-01-20 Searle & Co Kombinationer der omfatter en cyclooxygenase-2 hæmmer samt en leukotrien A4 hydrolasehæmmer, som har immunsuppressive virkninger
US6110994A (en) * 1996-06-14 2000-08-29 Cabot Corporation Polymeric products containing modified carbon products and methods of making and using the same
US6110944A (en) 1997-03-12 2000-08-29 G. D. Searle & Co. LTA4, hydrolase inhibitors
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
US6432976B1 (en) 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
US6559140B2 (en) 2000-03-09 2003-05-06 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
MY137020A (en) 2000-04-27 2008-12-31 Abbott Lab Diazabicyclic central nervous system active agents
FR2831884B1 (fr) * 2001-11-02 2003-12-26 Pf Medicament Nouveaux derives amides heteroaromatiques de 3 beta-amino azabicyclooctane, leur procede de preparation et leurs applications en therapeutique
US7152144B2 (en) 2002-05-29 2006-12-19 Hitachi, Ltd. Centralized storage management method
US7329682B2 (en) * 2003-04-03 2008-02-12 Ewha University-Industry Collaboration Foundation Method for inhibiting 5-lipoxygenase using a benzoxazole derivative
SE0301373D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
WO2004103959A2 (en) 2003-05-16 2004-12-02 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
ATE403654T1 (de) * 2003-07-28 2008-08-15 Janssen Pharmaceutica Nv Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren
CN1874991A (zh) 2003-08-29 2006-12-06 小野药品工业株式会社 能够结合s1p受体的化合物及其药物用途
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
TW200610761A (en) 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
US7750158B2 (en) 2004-06-22 2010-07-06 Schering Corporation Cannabinoid receptor ligands
GB2415818B (en) 2004-06-30 2008-12-31 Autoliv Dev Arrangement for triggering a vehicle safety device
RU2409565C2 (ru) 2004-09-13 2011-01-20 Оно Фармасьютикал Ко., Лтд. Азотистые гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента
JP2008536825A (ja) 2005-03-31 2008-09-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ フェニルおよびピリジルｌｔａ４ｈモジュレータ
ES2277745B1 (es) 2005-06-14 2008-06-01 Laboratorios Almirall S.A. Derivados n-amida de 8-azabiciclo /3.2.1/oct-3-ilo como antagonistas de ccr1.
GB0514018D0 (en) 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
PT1976828T (pt) 2005-12-29 2017-03-10 Celtaxsys Inc Derivados de diamina como inibidores de leucotrieno a4 hidrolase
US20090156465A1 (en) 2005-12-30 2009-06-18 Sattigeri Jitendra A Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors
WO2007146066A2 (en) 2006-06-06 2007-12-21 Critical Therapeutics, Inc. Novel piperazines, pharmaceutical compositions and methods of use thereof
WO2008016811A2 (en) 2006-07-31 2008-02-07 Neurogen Corporation Aminopiperidines and realted compounds
EP2121676A1 (en) * 2006-12-19 2009-11-25 Auspex Pharmaceuticals, Inc. Preperation and utility of ccr5 inhibitors
TW200906396A (en) 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof
US7935725B2 (en) * 2007-10-31 2011-05-03 Janssen Pharmaceutica Nv Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase
AU2009234140B2 (en) 2008-04-11 2013-04-11 Janssen Pharmaceutica Nv Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase

Also Published As

Publication number Publication date
HN2010002074A (es) 2012-12-03
EP2336125B1 (en) 2013-01-09
PH12013500094A1 (en) 2015-02-23
EA018802B1 (ru) 2013-10-30
ES2440746T3 (es) 2014-01-30
IL208480A (en) 2014-11-30
PL2336125T3 (pl) 2013-06-28
UY31760A (es) 2009-11-10
NZ588341A (en) 2012-06-29
CA2721099A1 (en) 2009-10-15
US20090258854A1 (en) 2009-10-15
RS52712B (en) 2013-08-30
CA2721099C (en) 2017-04-25
RS53081B (en) 2014-06-30
KR20110013386A (ko) 2011-02-09
TW201420100A (zh) 2014-06-01
JP5675943B2 (ja) 2015-02-25
DK2336125T3 (da) 2013-04-08
AU2009234140B2 (en) 2013-04-11
HRP20131192T1 (hr) 2014-01-17
PL2268646T3 (pl) 2014-02-28
CO6260069A2 (es) 2011-03-22
HK1152041A1 (en) 2012-02-17
ES2400875T3 (es) 2013-04-15
PT2268646E (pt) 2013-12-10
IL226244A (en) 2014-12-31
KR101228378B1 (ko) 2013-01-31
US20110159563A1 (en) 2011-06-30
JO2911B1 (en) 2015-09-15
IL208480A0 (en) 2010-12-30
TWI461196B (zh) 2014-11-21
US20110190503A1 (en) 2011-08-04
AU2009234140A1 (en) 2009-10-15
SV2010003694A (es) 2011-03-17
EA201071186A1 (ru) 2011-06-30
US8357684B2 (en) 2013-01-22
AR072353A1 (es) 2010-08-25
SI2336125T1 (sl) 2013-04-30
WO2009126806A2 (en) 2009-10-15
HRP20130278T1 (en) 2013-06-30
SI2268646T1 (sl) 2013-12-31
HK1158208A1 (en) 2012-07-13
WO2009126806A3 (en) 2010-03-18
WO2009126806A8 (en) 2010-11-18
EP2336125A1 (en) 2011-06-22
PT2336125E (pt) 2013-03-18
EP2268646B1 (en) 2013-10-02
EP2268646A2 (en) 2011-01-05
CN102056933A (zh) 2011-05-11
CY1114628T1 (el) 2016-10-05
CL2009000877A1 (es) 2009-11-27
US7939527B2 (en) 2011-05-10
BRPI0911336A2 (pt) 2021-06-29
JP2011516571A (ja) 2011-05-26
PE20091779A1 (es) 2009-11-14
PH12013500094B1 (en) 2015-02-23
MX2010011154A (es) 2010-12-21
EP2268646B9 (en) 2014-11-19
ZA201008054B (en) 2012-04-25
TW201002320A (en) 2010-01-16
NZ599853A (en) 2012-08-31
JP5530423B2 (ja) 2014-06-25
ECSP10010558A (es) 2010-11-30
DK2268646T3 (da) 2013-11-18
JP2014144949A (ja) 2014-08-14
IL226244A0 (en) 2013-06-27
CN102056933B (zh) 2014-09-17
MY157597A (en) 2016-06-30

Similar Documents

Publication Publication Date Title
NI201000168A (es) Aminas de tiazolopiridina-2-iloxi-fenil y tiazolopirazina-2-iloxi-fenil como moduladores del leucotrieno a4 hidrolasa.
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
BR112017003111A2 (pt) composições e métodos para o tratamento de distúrbios neurológicos
MX380777B (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
CU20120034A7 (es) Compuestos y composiciones como inhibidores de cinasa de proteína
MX379016B (es) Composiciones y metodos para tratar enfermedad de gaucher.
UY30479A1 (es) Moduladores de benzofuro- y benzotienopirimidina del receptor de histamina h4
CR20110103A (es) Heteroarilos sustituidos
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CR20150186A (es) Derivados tricíclicos de quinolinas y de quinoxalinas
CR11284A (es) Sulfonamidas como moduladores de trpm8
CL2012003421A1 (es) Compuestos derivados de 3-amino-n-(4-carbamoilpiridin-3-il)(aril/heteroaril)-2-carboxamida; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad del snc, oncologica, entre otras. pct fase nacional
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CR20110029A (es) Moduladores de diamino-piridina, pirimidina, y piridazina del receptor h4 de histamina
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
BR112012008004A2 (pt) compostos e composições como moduladores da atividade de gpr119
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CL2015002434A1 (es) Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina.
UY31340A1 (es) Moduladores tieno- y furo-pirimidina del receptor de histamina h4
PA8808201A1 (es) Moduladores imidazolo-,oxazolo-, y tiazolopirimidina del trpvi
CL2012001031A1 (es) Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros.
UY32641A (es) Compuestos con dos porciones heteroarilo bicíclicas fusionadas como moduladores de la hidrolasa de leucotrieno a4
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX2013001612A (es) Moduladores de trpv3 novedosos.
MX2015015194A (es) Metodo de tratamiento de la enfermedad por anestesia auricular de los nervios craneales.